Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Titan Biotech's Revenue for the
three
months ended in Jun. 2026 was ₹592 Mil. Titan Biotech's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹228 Mil.
Hence, Titan Biotech's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.59.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Titan Biotech Receivables Turnover Related Terms
Titan Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Titan Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a Receivables Turnover of 2.59 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Titan Biotech and its competitors. According to the industry distribution chart, Titan Biotech ranks #207 out of 848 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Titan Biotech's Receivables Turnover too high?
Titan Biotech's current Receivables Turnover is 2.59. The Biotechnology industry median Receivables Turnover is 5.28. Titan Biotech's value of 2.59 is 50.9% below this industry median. Based on the distribution chart, Titan Biotech ranks #207 out of 848 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #207 out of 848 companies for Receivables Turnover. This places Titan Biotech in the top 24% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. Titan Biotech's value of 2.59 is 50.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Titan Biotech's current Receivables Turnover of 2.59 is 50.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Titan Biotech and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Titan Biotech's current Receivables Turnover is 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹162.01, compared to a current price of ₹378.75 — trading 133.8% above its estimated fair value. The current Receivables Turnover is 2.59 and 50.9% below the Biotechnology industry median of 5.28. Titan Biotech's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Receivables Turnover is 2.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹378.75 is trading 133.8% above its estimated GF Value™ of ₹162.01.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Receivables Turnover: 2.59
GF Value™: ₹162.01 vs. price of ₹378.75 (133.8% above fair value)
Industry Position: 50.9% below the Biotechnology median (#207 of 848)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score
Get the complete analysis for BOM:524717
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
